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Abstract
The SRP-Sec61 targeting/translocation pathway of eukaryotic cells targets nascent protein
chains to the membrane of the endoplasmic reticulum. Using this machinery, secretory pro-
teins are translocated across this membrane whereas membrane proteins are integrated
into the lipid bilayer. One of the key players of the pathway is the protein-conducting Sec61
(translocon) complex of the endoplasmic reticulum. The Sec61 complex has no enzymatic
activity, is expressed only intracellularly and is difficult to purify and to reconstitute. Screen-
ing for small molecule inhibitors impairing its functions is thus notoriously difficult. Such
inhibitors may not only be valuable tools for cell biology, they may also represent novel anti-
tumor drugs. Here we have developed a two-step, sequential screening assay for inhibitors
of the whole SRP-Sec61 targeting/translocation pathway which might include molecules
affecting Sec61 complex functions. The resulting hit compounds were analyzed using a
whole cell biosynthesis assay and a cell free transcription/translation/translocation assay.
Using this methodology, we identified novel compounds inhibiting this pathway. Following
structure-based back screening, one of these substances was analyzed in more detail and
we could show that it indeed impairs translocation at the level of the Sec61 complex. A
slightly modified methodology may be used in the future to screen for substances affecting
SecYEG, the bacterial ortholog of the Sec61 complex in order to derive novel antibiotic
drugs.
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Introduction
During the early stages of intracellular protein transport, nascent secretory and integral mem-
brane proteins are synthesized at cytosolic ribosomes and must then be targeted to the mem-
brane of the endoplasmic reticulum (ER), a process which is mediated by the SRP-Sec61
targeting/translocation pathway, a well described mechanism even at the structural level [1, 2].
Targeting of the proteins to the ER membrane is mediated by signal sequences. Two types of
signal sequences are known: signal anchor sequences of integral membrane proteins, which
are part of the mature proteins (usually transmembrane domain 1), and signal peptides of
membrane and secretory proteins which are located at the extreme N terminus. Signal peptides
are cleaved off during protein maturation. As soon as signal sequences of the nascent chains
(NC) emerge at the translating ribosomes, they are bound by the signal recognition particle
(SRP). Translation is slowed down and the resulting ribosome/NC/SRP complex is targeted to
the heterodimeric SRP receptor at the ER membrane and from there to the Sec61 complex.
The Sec61 complex contains the protein-conducting Sec61α channel subunit and the Sec61β
and Sec61γ subunits. The NC is handed over to Sec61α, and the SRP/SRP receptor are disas-
sembled by GTP hydrolysis, a complex reaction which was recently analyzed in more detail
[3]. Following a tight interaction between the ribosome and the Sec61 complex, the signal
sequence is involved in destabilization of the closed conformation of Sec61α causing the relo-
cation of its plug domain (translocon gating). Translation accelerates, secretory proteins are
translocated through the protein-conducting channel into the ER lumen whereas their signal
peptides leave the protein-conducting channel at a lateral gate. Through this cleavage, secre-
tory proteins are released into the ER lumen. Signal anchor sequences a well as the other trans-
membrane domains of integral membrane proteins are released through the lateral gate of the
protein-conducting channel and become part of the ER membrane. The Sec61 complex is sta-
bly and transiently associated with supporting proteins such as the binding immunoglobulin
protein (BiP, HSP70 chaperone family), Sec63 (HSP40 chaperone family), the translocating
chain-associated membrane protein (TRAM), the translocon-associated protein complex
(TRAP) and the oligosaccharyl transferase complex (OST).
For a pharmacological application, two types of inhibitors of the SRP-Sec61 targeting/trans-
location pathway may be important: those blocking the protein-conducting channel Sec61α in
general thereby inhibiting the biosynthesis of all proteins using this pathway (broad ranging
inhibitors, type A) and those blocking the function of individual signal sequences thereby
inhibiting the biosynthesis of specific proteins (specific inhibitors, type B). Although a rather
limited amount of studies addressed such inhibitors, some progress was made in the recent
years.
Compounds targeting the Sec61 complex were identified more or less by chance during
screens for inhibitors of the expression of specific proteins [4]. During a screen for inhibitors
of the expression of cell adhesion molecules, the fungal compound HUN-7293, a cyclic hepta-
depsipeptide, was identified [5]. It was shown that HUN-7293 inhibits cotranslational translo-
cation at the level of the Sec61 complex by a signal sequence-discriminative mechanism of
action [6]. Similar results were reported for the cyclic heptadepsipeptide cotransin, which rep-
resents a simplified HUN-7293 derivative [7]. Originally, it was thought that these cyclodepsi-
peptides act rather selectively at the Sec61 complex affecting only the biosynthesis of a small
group of proteins [6], [7] but more highly sensitive proteins were described in the following
years [8–10]. A recent proteomic study for cotransin revealed, that at higher saturating con-
centrations, the biosynthesis of almost all secretory proteins was sensitive whereas the majority
of integral membrane proteins remained cotransin-resistant [11]. The mechanism of action of
cotransin and the related cyclodepsipeptides is still not completely clear. The
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cyclodepsipeptides mentioned above represent mixed type A/type B inhibitors (which means
that they are selective rather than being broad range or specific inhibitors) which seems to pre-
clude their pharmacological application.
Mycolactone, an immunosuppressive macrolide released by the human pathogen Mycobac-
terium ulcerans was recently shown to block transfer of secretory and integral membrane pro-
teins at the Sec61 complex [12]. Mechanistically, it seems to perturb an interaction between
the ribosome and Sec61α which is necessary for cotranslational translocation to progress [13].
Recent proteomic analyses, however, identified also mycolactone-resistant integral membrane
proteins [14] suggesting that this compound has also a certain type of substrate selectivity at
Sec61α which is however, much broader than that of the cyclodepsipeptides mentioned above.
Another compound, namely Eeyarestatin I was shown to inhibit the ER associated degradation
pathway ERAD) [15] but also acts at the level of the Sec61 complex where it prevents transfer
of the NC from the targeting machinery to the Sec61 complex [16]. Moreover, it was shown
that the compound inhibits retrograde transport pathways back to the ER in the case of at least
some endocytosed proteins such as diphtheria toxin [17]. The natural compound apratoxin
also inhibits Sec61α, most likely by binding to its lateral gate [18, 19]. Its actual selectivity,
however, needs to be determined.
The available data for type B inhibitors of the SRP-Sec61 targeting/translocation pathway,
i.e. those which interfere with specific signal sequences and consequently inhibit biosynthesis
of specific proteins, are even more limited. The recently described compound cyclotriazadisul-
fonamide (CADA), however, binds specifically to the signal sequence of the human cluster of
differentiation 4 protein (CD4), the cellular receptor for HIV. CADA inhibits CD4 biosynthe-
sis at Sec61α, most likely by preventing a reorientation step of the signal sequence in the pro-
tein-conducting channel [20]. Only one additional protein, namely sortilin, was found to be
sensitive in a proteomic study [21].
The setup of a high throughput screening assay for small molecule inhibitors of the
SRP-Sec61 targeting/translocation pathway, in particular for the Sec61 complex, is very diffi-
cult since Sec61α has no enzymatic activity and is expressed only in the ER membrane. Here
we set up a novel two step cellular screening assay allowing to identify both, type A and type B
inhibitors (type B inhibitors could only be detected for the specific screening target, see
below). With the help of this assay, we were able to identify novel compounds inhibiting
cotranslational translocation at the Sec61 complex.
Material and methods
Plasmids and cloning
Standard DNA manipulations were carried out. The following G protein coupled receptors
(GPCRs) were fused C-terminally with the enhanced green fluorescent protein (GFP) thereby
replacing the stop codons using the vector plasmid pEGFP-N1 (Clontech, Mountain View,
CA, USA): rat corticotropin-releasing factor receptor type 1 (CRF1R; residues M1-T413), rat
corticotropin-releasing factor receptor type 2a (CRF2(a)R; residues M1-V411), human luteiniz-
ing hormone receptor (LHR; residues M1-C699), human protease-activated receptor 1 (PAR1;
residues M1-T425), human thyrotropin receptor (TSHR; residues M1-L764), human endothe-
lin B receptor (ETBR; residues M1-S442) and the human vasopressin V2 receptor (V2R; resi-
dues M1-K367). The resulting constructs were CRF1R.GFP, CRF2(a)R.GFP, LHR.GFP, PAR1.
GFP, TSHR.GFP, ETBR.GFP and V2R.GFP respectively. The human water channel protein
aquaporin 2 (AQP2; residues M1-K270) was also fused C-terminally with GFP using the same
vector plasmid (resulting construct AQP2.GFP).
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For the primary and secondary screens, stable transfected HEK 293 cell clones were derived
expressing CRF1R.GFP and unfused GPP respectively under the control of the Tet-On pro-
moter. To this end, both constructs were cloned into the pTRE-Tight vector of the Tet-On
Advanced Inducible Gene Expression Systems (Clontech, Heidelberg, Germany). Establishing
of the Tet-On system was carried out according to the supplier’s recommendations.
For the fusion of the signal peptide of the CRF1R to the preprolactin marker, the previously
described plasmid pGEMBP1 encoding bovine preprolactin (pPL) was used [22]. Similar to a
previous study [21], inverse PCR-based site-directed mutagenesis was used to replace the pPL
signal peptide in pGEMBP1 with the N-terminal 30 residues of the CRF1R (23 residues of sig-
nal peptide + 7 residues of mature CRF1R). The resulting construct was designated CRF1R-
pPL.
Cell culture
HEK 293 cells were cultured at 37˚C and 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM, low glucose, GlutaMAX) containing 10% (v/v) fetal calf serum (FCS), penicillin (100
U/ml) and streptomycin (100 μg/ml).
High-throughput fluorescence assay for the primary and secondary
screens, concentration response validation, and data analysis
Using a microplate dispenser (EL406, Biotek), 30 μl of cell suspensions in DMEM were seeded
into assay plates (black-wall with clear bottom cell-binding surface, 3683; Corning, NY, USA)
in an initial density of 12,000 cells/well. The assay plates were incubated at 37˚C, 5% CO2 in a
humidity-controlled incubator for 24 h. Library compounds were dissolved to a final concen-
tration of 10 mM in DMSO in columns 1 to 22 of a 384-well microtiter compound mother
plate. Thereafter, 0.2 μl of compounds were transferred to a 384-well plate containing 40 μl
DMEM (final compound concentration 50 μM) using a robotic liquid handler equipped with a
384-channel fixed-tip pipetting head (Freedom Evo, Tecan, Ma¨nnedorf, Switzerland). 10 μl of
this pre-diluted compound solutions were then transferred to the assay plates (using the same
liquid handling equipment) and the plates were incubated for 1 h at 37˚C to allow compound
interaction with the target prior to induction of the GFP sensor construct. In a second microti-
ter plate containing DMEM, the inducer doxycyclin was added to a concentration of 5 μg/ml
into columns 1 to 23, while column 24 received only medium. This scheme was applied to cre-
ate positive controls in column 23 (induced cells without compound addition, 100% signal)
and negative controls in column 24 (non-induced cells, 0% signal). Of this doxycyclin solution,
10 μl was transferred to the assay plates to induce GFP expression, giving the final assay condi-
tions: 50 μl of cell growth medium, 10 μM of compound, and 1 μg/ml of doxycycline (where
appropriate). Assay plates were incubated for another 48 h, and then the growth medium was
removed to a residual volume of 10 μl using a microplate washer (Hydrospeed, Tecan) in
order to reduce background fluorescence. GFP fluorescence was then measured in a micro-
plate reader (Safire2, Tecan) with an excitation wavelength of 498 nm and an emission wave-
length of 512 nm, with 5 nm bandpass each, and fluorescence reading from the bottom of the
plate.
For concentration response validation of the compounds, 29 samples were rearranged from
the compound store by placing 5 μl aliquots of 10 mM solutions onto columns 1 and 12 of a
384-well plate. Serial dilutions of the compounds were prepared by adding 5 μl DMSO to the
compound samples, and transferring 5 μl of the diluted sample to the adjacent empty column.
11 consecutive serial 2-fold dilutions were prepared within the compound plate using a robotic
liquid handler equipped with a 384-channel disposable tip head (tips were disposed after each
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pipetting step to ensure accuracy of the serial dilution). Compound samples were then diluted
by transferring 1.6 μl to a 384-well plate containing 80 μl of DMEM, yielding 100 μM solutions.
10 μl of the pre-diluted solutions were transferred to the assay plates containing cells in 30 μl
medium. Samples were incubated for 1 h at 37˚C, and 10 μl of doxycycline pre-dilutions were
added for target induction (final compound concentrations ranging from 0.02 μM to 20 μM).
Fluorescence measurements were carried out as described above.
For the data analysis, percent activities were calculated for each measured sample by nor-
malizing its readout to the medians of the plate control samples. To assess for statistical signifi-
cance of a value, Z-scores were calculated for each sample [23]. For monitoring the integrity of
the signal window, the Z’-factor was calculated for each plate using its positive and negative
control samples [24]. Data were pre-processed (data normalization and initial quality control)
using in-house software. Reports containing chemical structures and calculation of molecular
properties were derived using Pipeline Pilot (BIOVIA, San Diego, CA, USA). IC50 values were
determined by applying the four-parameter log-logistic function of the “drc” R-package for
calculating concentration-response models [25]. Percent activity values were plotted against
compound concentration, graphics were prepared using the R-statistics framework (R. C.
Team, R Foundation for Statistical Computing, Vienna, Austria, 2016).
Structure-based back screening and identification of FMP-401319
analogous compounds
The compounds were identified using the Tanimoto Molecular Similarity tool embedded in
Pipeline Pilot and our in-house Database of Available Chemical Substances (DACS) contain-
ing ~38 million unique chemical structures coming from 43 different vendors (http://www.
open-dacs.de/). According to a Tanimoto threshold of 0.6, 45 analogues of FMP-401319 were
identified and thoroughly validated based on structure activity considerations. Compounds
were purchased from commercial vendors and solubilized in DMSO.
Whole cell flow cytometry biosynthesis inhibition assay
4.5 x 105 HEK 293 cells were grown on 12-well plates for 24 h and transiently transfected with
1.2 μg plasmid DNA/well and polyethylenimine (PEI, Polysciences Europe GmbH, Eppelheim,
Germany) according to the supplier’s recommendations. After 4.5 h of incubation, cells were
treated for 19 h with compounds dissolved in DMSO (FMP-503533, 20 μM; FMP-214534
25 μM; FMP-401319 and its analogous substances, 25 μM; FMP-208236, 20 μM; FMP-214219,
10 μM) or cycloheximide (20 μg/ml) or DMSO alone (negative control). Variable concentra-
tions of the compounds FMP-503533, FMP-214534, FMP-401319, FMP-208236, FMP-
214219) were used due to the different IC50 values obtained for each compound in the screen-
ing assay. The final DMSO concentration in all samples was 1%. Cells were washed twice with
PBS and the GFP fluorescence signals were quantified by flow cytometry using a FACSCalibur
system (BD Biosciences, USA). Total fluorescence intensity of 1 x 104 cells was analyzed for
each sample using the BD CellQuest Pro software (BD Biosciences, USA). Normalization of
the total amount of GFP fluorescence was realized by subtracting the background of non-
transfected HEK 293 cells. The portion of the GFP fluorescence present at time t0 of com-
pound treatment (proteins synthesized after transfection during the 4.5 h incubation time
which may endure thereafter the compound incubation time) was eliminated by subtracting
the value of cycloheximide-treated cells.
Screening assay for inhibitors of the Sec61 complex
PLOS ONE | https://doi.org/10.1371/journal.pone.0208641 December 13, 2018 5 / 23
Cell free transcription/translation and translocation assay
Truncated CRF1R-pPL NCs of 78 residues without a stop codon were first generated by stan-
dard PCR from pGEM plasmids, and subsequently transcribed in vitro using T7 RNA poly-
merase (RiboMAX system, Promega, Madison Wi, USA). Purified RNA was translated in
rabbit reticulocyte lysate (Promega) in the presence of L-[35S]-methionine (PerkinElmer,
Waltham, MA, USA). Translations were performed at 25˚C for 20 min in the absence of
microsomes. Pancreatic microsomes (RM) from sheep [26] were pre-treated with compound
or DMSO control for 15 min at room temperature. Next, microsomes were added to the trans-
lation mixture and incubated for 10 min on ice, followed by 10 min incubation at 25˚C.
Release of the NCs from the targeted ribosome was induced by treatment with 2 mM puromy-
cin (PU) for 7 min at 25˚C. Equal aliquots of each sample were left untreated of were treated
with proteinase K (PK, Roche, Basel, Switzerland). Digestion with PK was performed on ice
for 30 min and quenched by the addition of phenylmethylsulfonyl fluoride (PMSF; Thermo
Fisher Scientific, Waltham, MA, USA). Finally, 10 μl reaction mixtures were diluted with
300 μl low-salt buffer (80 mM KOAc, 2 mM Mg(OAc)2, 50 mM HEPES, pH 7.6), and radiola-
beled proteins were centrifuged for 10 min at 21,382 x g and 4˚C (Hettich 200R centrifuge
with 2424-B rotor). The supernatant was removed, and the pellet was resuspended in 30 μl
Laemmli sample buffer for analysis by SDS-PAGE. Quantitative analysis of translocation
experiments was performed on a Cyclone Plus phosphor imager system (PerkinElmer) with
accompanying software.
For the time-of-addition experiments, NCs were translated without microsomes as
described above. In the mean-time, sheep pancreatic microsomes were pre-treated either with
compound or with DMSO (control). After 20 min of translation, the translation mixture was
split in 4 aliquots. Next, one aliquot received the compound pre-treated microsomes whereas
the other 3 aliquots were given the control DMSO-treated microsomes. All samples were then
incubated for 10 min on ice and 5 min at 25˚C. The last 2 aliquots received either DMSO (con-
trol sample) or compound, and all samples were incubated for another 5 min at 25˚C before
treatment with PU. NCs were isolated by sedimentation at 4˚C and pellets were dissolved in
SDS sample buffer for analysis by SDS-PAGE as described above.
Statistics
For the statistics of the screening procedures, data analysis and IC50 determination of the ini-
tial hit compounds, see above. Biosynthesis inhibition of the various membrane proteins by
the compounds in the cellular assays and translocation inhibition in the cell free in vitro trans-
lation assays were analyzed using a One-way ANOVA test (Dunnett’s Multiple Comparison
Test). In the case of the cellular assay, mean values were calculated out of 3–10 independent
experiments indicated in the figures ± SD. For the translocation inhibition experiments, mean
values ± SD were calculated out of 2 or 3 independent experiments as listed in the S1 Table. P
values: p� 0.001 (���), p� 0.01 (��), p� 0.05 (�), p� 0.1 (not significant, ns). GraphPad
Prism Software, (La Jolla, CA, USA) was used in each case for statistics.
Results and discussion
Development and implementation of the high throughput screening
strategy
Taking the experimental obstacles mentioned above into account, we decided to establish a
whole-cell screening approach involving two steps: first, inhibitors for transcription,
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translation and the SRP-Sec61 targeting/translocation pathway are selected (primary screen),
then as a second step, inhibitors of transcription/translation are deselected (secondary screen)
(Fig 1).
For the primary selection screen, we used the GFP-tagged CRF1R (CRF1R.GFP) as a target.
The CRF1R was used, because it represents a well-studied GPCR which is highly expressed in
the plasma membrane in comparison to other GPCRs. Moreover, it was experimentally con-
firmed that it passes the SRP-Sec61 targeting/translocation pathway by using its cleavable sig-
nal peptide [27]. Another advantage of taking a GPCR is that these receptors form the largest
protein family in eukaryotic cells, which allows later on to analyze cross-selectivity of identified
compounds on comparable protein targets. Since SRP binding to the N-terminal signal peptide
of CRF1R.GFP should slow down or arrest translation, inhibitors of the SRP-Sec61 targeting/
Fig 1. Scheme of the primary and the secondary screening procedures. In the primary screen (upper panel), construct CRF1R.GFP was used, a GFP-tagged GPCR
possessing a cleavable signal peptide which uses the SRP-Sec61 targeting/translocation pathway. The secondary screen (lower panel) was performed with unfused,
soluble GFP which does not use the SRP-Sec61 targeting/translocation pathway. See the text for details.
https://doi.org/10.1371/journal.pone.0208641.g001
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translocation pathway should decrease or even prevent CRF1R.GFP biosynthesis and conse-
quently expression of the C-terminal GFP tag. The construct CRF1R.GFP was stably trans-
fected in HEK 293 cells under the control of the Tet-On promoter. Without induction, the
CRF1R showed almost no expression in these cells leading to a very good signal to noise ratio
following induction which was an additional argument to take this receptor for our screening
experiments. Cells grown on 384-well plates were pre-treated with the library compounds
(10 μM each) for 1 h. The library encompassed 37,312 pre-selected substances with derived
scaffolds based on the World Drug Index (WDI) (32,736) [28] and compound donations from
academic research labs (4,576). Following pre-treatment of the cells with the compounds,
CRF1R.GFP expression was induced and receptor expression was quantified by measuring the
appearing GFP fluorescence signals. 1075 compounds significantly decreased receptor expres-
sion (z-score of the fluorescence signal < -3) in the primary screen, of which the 1052 most
active compounds were re-picked onto new compound mother plates. The set of 1052 com-
pounds was supposed to contain specific inhibitors for the SRP-Sec61 targeting/translocation
pathway, inhibitors of transcription/translation, but also many stochastic false positives that
would not confirm upon repetition of the measurement. A secondary deselection screen was
thus performed using unfused, cytosolic GFP protein under the control of the Tet-on pro-
moter as a target. This construct does not use the SRP-Sec61 targeting/translocation pathway
and its expression depends only on transcription and translation. To identify compounds spe-
cific for the SRP-Sec61 targeting/translocation pathway, the 1052 compounds were re-mea-
sured under selection conditions in three technical replicates, and in parallel under deselection
conditions also in three technical replicates at a concentration of 10 μM. 28 compounds repro-
ducibly behaving as inhibitors in the selection screen, but not in the deselection screen, were
considered to represent real hits. A graphical depiction of the activities of these 1052 hit com-
pounds is shown in Fig 2.
We assessed each compound for identity and purity by analytical liquid chromatography–
mass spectrometry (LC-MS) experiments with a threshold of>90% purity. Using the same
assay on 384-well plates with the 29 serially diluted compounds, the substances were rated
with regard to their IC50 value for decreasing CRF1R.GFP expression (cut off = 15 μM). More-
over, we avoided compounds non-compliant to relevant descriptors of general drug-likeness
such as the Lipinski‘s “rule of five” (H donors, H acceptors, hydrophobicity, molecular mass)
[29] and having a polar surface area (PSA) smaller than 140 Å2 [30] and Pan-assay interference
compounds (PAINS; chemical compounds that are often false positive). In addition, we per-
formed a database substructure search (ChEMBL, Chemical abstract, and our internal data-
base) to evaluate potential biological activities and interference patterns of the identified
chemotypes such as promiscuous binders to non-related protein targets. We focused on com-
pounds that were neither over-represented as hits from in-house databases nor from curated
online databases (Chemical abstract and ChEMBL) since frequent hit molecules could compli-
cate downstream analyses. Finally, 5 hit structures possessing different chemotypes (FMP-
503533, FMP-214534, FMP-401319, FMP-208236 and FMP-214219) remained for further vali-
dation analysis (Fig 3).
Confirmation of the mode of action of the identified compounds by
cellular and cell free assays
We next addressed the selectivity of the compounds for biosynthesis inhibition in a cellular
assay. To this end, HEK 293 cells were transiently transfected with various GFP-tagged integral
membrane proteins, namely AQP2.GFP, CRF2(a)R.GFP, ETBR.GFP, LHR.GFP, PAR1.GFP,
TSHR.GFP, V2R.GFP and the original screening target CRF1R.GFP. The main interest of this
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study was to identify novel type A inhibitors of the Sec61 complex. Integral membrane pro-
teins were chosen for this assay because the vast majority of them were resistant to mixed type
A/type B inhibitors [11], such as cotransin, which we aimed to exclude from further analysis.
Cells expressing the constructs were treated with the compounds or DMSO solvent or
cycloheximide. After 19 h of incubation, the total GFP fluorescence of 1 x 104 cells was ana-
lyzed using flow cytometry as a measure of membrane protein biosynthesis. To avoid falsifica-
tion of the results by proteins already synthesized at t0 of compound treatment, cycloheximide
values were subtracted. Compounds FMP-214534, FMP-401319, FMP-208236 and FMP-
214219 inhibited biosynthesis of all target proteins albeit with different efficiencies (Fig 4).
Fig 2. Schematic depiction of the results of the 1052 hit compounds under selection and deselection conditions. For each compound
(dots), the relative GFP fluorescence of the screening target in the primary screen (CRF1R.GFP) was plotted against the relative GFP
fluorescence of the target in the secondary screen (soluble, unfused GFP). Hit compounds are indicated in green, the 5 compounds used for
further analysis are indicated in red (see below). Data represent mean values of three technical replicates (see S1 Fig for the replicates). 100%
fluorescence = mean values of 16 induced plate control samples; 0% fluorescence = mean values of 16 non-induced plate control samples
(plate control samples were without compound).
https://doi.org/10.1371/journal.pone.0208641.g002
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Taken together, these results are consistent with a general inhibition of the SRP-Sec61 target-
ing/translocation pathway of these compounds (type A inhibitor). Substance FMP-503533, in
contrast, impaired only the biosynthesis of the original screening target CRF1R.GFP, suggest-
ing that it is more selective and might e.g. interfere with the signal sequence of CRF1R.GFP
(type B inhibitor).
We next performed a cell free assay to address the question whether the compounds indeed
inhibit the SRP-Sec61 targeting/translocation pathway (Fig 5). The principle of the assay was as
follows [20]: the signal sequence of the screening target CRF1R.GFP was fused N-terminally to the
mature protein part of bovine pre-prolactin (pPL) in order to replace the native pre-prolactin sig-
nal sequence, and a PCR fragment without stop codon encoding for a 78-residue truncated NC of
this CRF1R-pPL chimaera was synthesized (78mer; CRF1R-pPL see S2 Fig for the sequence and
build-up of the construct). The purified PCR fragment was first transcribed in vitro using T7
RNA polymerase and subsequently translated in a cell free rabbit reticulocyte lysate mixture in the
presence of radiolabeled [35S] methionine. Addition of pancreatic rough microsomal membranes
(RM) resulted in docking of the ribosome-nascent chain complexes (RNCs) via the SRP receptor
to the Sec61 complex and the NCs could engage Sec61α. However, due to the lack of the stop
codon, the NCs were unable to complete translation/translocation and remained bound to the
ribosomes via an intact peptidyl-tRNA bond (NC-tRNA). The NCs were thereafter released from
the ribosomes (that are docked onto the protein-conducting Sec61α channel) by puromycin (PU)
allowing not only full translocation into the ER lumen but also signal peptide cleavage by the sig-
nal peptidase (signal peptide-cleaved NCs; SPcNC). Using this assay, we could show that com-
pounds FMP-503533, FMP-214534, FMP-401319 and to a slightly lesser extend FMP-214219
significantly inhibited translocation and processing of CRF1R-pPL (p< 0.0001) whereas com-
pound FMP-208236 only had a minor effect on translocation inhibition, although with borderline
significance (18% reduced translocation; p = 0.0467) (Fig 5A, the red arrow indicates the SPcNC
fragment, i.e. the translocated CRF1R-pPL without signal peptide). We used a rather high concen-
tration of the compounds in this assay (300 μM each), since previously published data for e.g.
cotransin [7] and CADA [20] suggested that the IC50 values for biosynthesis inhibition at the
Sec61 complex may be substantially higher in the cell free assay in comparison to a cellular assay.
The reason for this discrepancy is not clear but it may be speculated that substantial amounts of
these hydrophobic compounds dissolve in an unproductive way in the microsomal membranes
which are present in excess.
These results show that compounds FMP-503533, FMP-214534, FMP-401319 and FMP-
214219, indeed target the SRP-Sec61 targeting/translocation pathway. The mechanism of
action of compound FMP-208236 remains elusive (although a general, non-Sec61 complex
related cytotoxicity may be at play). On the other hand, the fact that this compound was unable
to profoundly inhibit translocation and processing of CRF1R-pPL does not necessarily mean
that this compound does not target the SRP-Sec61 targeting/translocation pathway. Since the
components of the cell free assay need not to be synthesized and assembled as in whole cells,
this method represents a reconstituted system. If, for example, compound FMP-208236
behaved as an assembly inhibitor of the Sec61 complex, such a function would not be detected.
Fig 3. Chemical structures and properties of the compounds FMP-503533, FMP-214534, FMP-401319, FMP-208236 and FMP-214219. Left
panels. Chemical structures of the compounds. Central panels. Rating of the compounds (red line) for their fulfilment of “Lipinski’s rule of five” for
druggable compounds: H donors, H acceptors, hydrophobicity (ALogP), molecular mass (MW), and polar surface area (PSA). Calculation of the
physicochemical properties was made using the SwissADME server (www.swissadme.ch). Right panels. Concentration response curves for the
biosynthesis inhibition of the screening target CRF1R.GFP. The assay was carried out as in the primary screen using 384-well plates and different
concentrations of the compounds. Expression of CRF1R.GFP was quantified fluorometrically via its GFP signals. The IC50 values are indicated. Data
points are mean values of triplicates (±SD) and represent % of the maximal activity.
https://doi.org/10.1371/journal.pone.0208641.g003
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Fig 4. Whole cell assay: biosynthesis of various target proteins in HEK 293 cells treated with compounds FMP-503533, FMP-214534,
FMP-401319, FMP-208236 and FMP-214219. To analyze activity and selectivity of the compounds, HEK 293 cells were transiently
transfected with the original screening target CRF1R.GFP (red column) and various GFP-tagged integral membrane proteins. Cells were
treated with the compounds (FMP-503533, 20 μM; FMP-214534, 25 μM; FMP-401319, 25 μM; FMP-208236, 20 μM; FMP-214219, 10 μM)
or DMSO for 19 h and the total GFP fluorescence of the cells was analyzed using flow cytometry as a measure of biosynthesis. Note that
compounds FMP-214534, FMP-401319, FMP-208236 and FMP-214219 affected the biosynthesis of all target proteins whereas compound
FMP-503533 impaired only biosynthesis of the original screening target CRF1R.GFP. Columns represent mean values of biosynthesis (% of
matched DMSO control, red line) calculated out of 3–10 independent experiments indicated in the individual panels ±SD. P values:
p� 0.001 (���), p� 0.01 (��), p� 0.05 (�), p� 0.1 (not significant, ns).
https://doi.org/10.1371/journal.pone.0208641.g004
Fig 5. Cell free assay: activities of the compounds against the SRP-Sec61 targeting/translocation pathway. (A) Representative digital autoradiograms of the in vitro
transcribed/translated and translocated CRF1R-pPL chimaera in the absence or presence of the indicated compounds (300 μM). NCs of 78 residues without a stop
codon were transcribed/translated in vitro in the cell free rabbit reticulocyte lysate system. Because of an intact peptidyl-tRNA bond, NCs stay attached to the ribosome
and appear as NC-tRNA complexes (lane 1, NC-tRNA). Due to spontaneous hydrolysis of the peptidyl-tRNA bond, a fraction of the [35S]-labeled peptides is visible as
prematurely released NCs (lane 1, NC). Loaded ribosomes are subsequently mixed with RM (lanes 2–5, RM) to allow for ribosome docking onto the Sec61α protein-
conducting channels. Note that the presence of RM also releases extra NCs from tRNA in an unproductive way. Finally, NCs are released from the ribosomes by
addition of PU (lanes 4–5, PU), resulting in signal peptide-cleaved NCs that have been translocated into the ER lumen (SPcNC, 55 residues, red arrow). In the diagram
on the lower right panel, each black bar represents the relative amount of translocated protein versus total protein (translocated and precursor) after compound
treatment (lane 5), in comparison to the corresponding DMSO control (= 100% translocation; lane 4). Bars are mean ± SD.; n� 2. See also S1 Table for the data. P
values: p< 0.0001 (���), p� 0.05 (�). (B) Schematic depiction of the cell free assay following in vitro transcription/translation of construct CRF1R-pPL and addition of
RM. The effects of PU treatment (right panel) or leaving the sample untreated (left panel) on the NC-tRNAs are shown. See also (A) above for details. SP = signal
peptide; SPase = signal peptidase.
https://doi.org/10.1371/journal.pone.0208641.g005
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Substructure-based back screening and hit expansion of compound FMP-
401319
The next step was to look at the mechanism of action of the compounds in more detail, in par-
ticular to determine whether the compounds act at a pre-targeting step or at the level of the
Sec61 complex itself. However, as the number of active cluster members and an existing struc-
ture activity relationship (SAR) within the same chemotype can be considered as a further evi-
dence supporting the validity of a hit compound, we first performed a substructure based
back-screening for additional commercially available substances around the compounds
FMP-503533, FMP-214534 and FMP-401319. In the case of compound FMP-401319, a large
cluster of similar compounds bearing the pyrazolo[1,5-a]pyrimidine scaffold was commer-
cially available. We tested 45 analogues by the whole cell selectivity assay described above.
While some of the compounds showed a decreased activity (e.g. compounds FMP-401319-6,
FMP-401319-17 and FMP-401319-43), one compound (FMP-401319-3) exhibited a signifi-
cantly enhanced biosynthesis inhibition of some target proteins (AQP2, ETBR, V2R) in com-
parison to the parental hit FMP-401319 (see Fig 6 for exemplary results). Of note and for an
unknown reason, the PAR1 seems to be most sensitive for FMP-401319-3 and also for the
parental compound FMP-401319 (see Fig 4). In the case of PAR1, the protein sequence down-
stream (thus, C-terminal) to the signal peptide cleavage site of is auto-proteolytically released
as a peptide called parstatin, following receptor activation by thrombin [31]. Thus, the
sequence adjacent to the signal peptide of the PAR1 may not be simply exchangeable as it has
to match functionally to the preceding signal peptide to form a loop during Sec61α gating, like
it has been shown previously for the signal peptides and the downstream C-terminal sequences
of other membrane proteins [32, 33]. It remains to be determined whether such a hypothetic
functional match influences sensitivity in this case.
This experiment also allows a first insight into the underlying molecular recognition and
structure activity relationship of FMP-401319. For example, substitution of the benzo-
1,3-dioxolan group (eastern half of the molecule) by a chlorophenyl group led to a better inhib-
itory activity (FMP-401319-3) while substitution of the 5-chloro-indol group (western half of
the molecule) decreased inhibitory activity of the compound. This indicates that both distal
moieties at the pyrazolo[1,5-a]pyrimidine scaffold play an important role for its efficacy.
Moreover, we analyzed the compound in the cell free assay described above and found a
slightly increased inhibition of CRF1R-pPL translocation in comparison to the original com-
pound FMP-401319. The absolute IC50 values for translocation inhibition were 139 μM for
FMP-401319 and 98 μM for FMP-401319-3 (see also Fig 7 and S1 Table for the data). The IC50
values were obtained by calculating the amount of translocated protein versus total protein
(translocated and precursor), in comparison to the DMSO control (= 100% translocation).
The IC50 value determined for FMP-401319 in the whole cell experiment (10.6 μM; see Fig 3)
was roughly tenfold higher in the cell free assay. As already mentioned, a similar discrepancy
between the IC50 values in whole cell and cell free assays was observed in other studies for
inhibitors acting at the level of the Sec61 complex, e.g. for the more or less substrate-selective
compound cotransin [7] or CADA which inhibits highly selective the translocation of human
CD4 [20]. Due to the improved activity of FMP-401319-3, we focused for the subsequent stud-
ies on this compound.
Compound FMP-401319-3 acts in a post targeting step at the level of the
Sec61 complex
To determine whether a pre- or post-targeting step is affected by compound FMP-401319-3,
we repeated the cell free assay described above but equal aliquots of the translated/translocated
Screening assay for inhibitors of the Sec61 complex
PLOS ONE | https://doi.org/10.1371/journal.pone.0208641 December 13, 2018 14 / 23
Screening assay for inhibitors of the Sec61 complex
PLOS ONE | https://doi.org/10.1371/journal.pone.0208641 December 13, 2018 15 / 23
material were left untreated or were exposed to proteinase K (PK, see Fig 7A for a scheme of
the experiments). Another aim was to obtain additional information on how the ribosome
docks onto Sec61α and how the NC is inserted into the protein-conducting channel. NCs of
78 residues are bound to the ribosome as peptidyl-tRNAs with about 30 residues buried inside
the ribosome tunnel. PK treatment of these free, non-Sec61 complex-bound ribosome nascent
Fig 6. Substructure-based back screening of compound FMP-401319. Left panel. Structure of the compounds. Right panel.
Commercially available derivatives of FMP-401319 (25 μM each) were tested for their inhibitory action in the whole cell biosynthesis assay
as described in the legend of Fig 3. While some of the compounds showed a decreased activity (exemplary results: compounds FMP-
401319-6, FMP-401319-17 and FMP-401319-43), one compound (FMP-401319-3) increased biosynthesis inhibition of some target
proteins in comparison to FMP-401319. Columns represent mean values of biosynthesis (% of matched DMSO control, red line)
calculated out of 5 independent experiments ±SD. P values: p� 0.001 (���), p� 0.01 (��), p� 0.05 (�), p� 0.1 (not significant, ns).
https://doi.org/10.1371/journal.pone.0208641.g006
Fig 7. Compound FMP-401319-3 inhibits cotranslational translocation of CRF1R-pPL concentration-dependently at the level of the Sec61 complex. (A)
Schematic depiction of the effects of PU, PK and a PU/PK combination on targeted and non-targeted ribosomes containing CRF1R-pPL NC-tRNAs in the cell free
transcripition/translation/translocation assay. See text for details. The individual panels of Fig 7A refer to the autoradiogram shown in 7B. (B) Representative digital
autoradiogram of the translated and translocated CRF1R-pPL chimaera in the absence or presence of different concentrations of compound FMP-401319-3 (3 μM,
30 μM, 300 μM), as described in the legend to Fig 5. All samples are with RM. Equal aliquots of the translated material were treated with PK (lanes 9–16, PK) or left
untreated (lanes 1–8). SPcNCs that have been translocated into the ER lumen (red arrow) are protected inside the microsomal vesicles and thus PK-resistant. Note that
at 300 μM of FMP-401319-3, most peptide chains could be rescued in the intact NC form after PK treatment (lane 14). (C) Interpretation of the results following FMP-
401319-3 treatment. Without compound treatment (left panel), the NC is fully translocated, the signal peptide is cleaved-off and the SPcNC fragment appears.
Treatment with FMP-401319-3 (right panel), however, interferes with a step before the growing peptide chain has been translocated and reached the luminal side of the
ER. Some NC may be positioned between ribosome exit tunnel and the cytosolic side of the Sec61 complex in such a way that some parts are exposed to the cytosol and
accessible in the experiment to PK. (D) Quantification of the data shown in Fig 7B and from 2 additional, independent experiments. Graph in upper panel shows the
percentage of translocation for different concentrations of compound FMP-401319-3, similar as explained in the legend to Fig 5A. Bars are mean of three digital
autoradiograms ± SD; n = 3. See also S1 Table for the data. Lower panel displays the results from equivalent experiments with the archetypical mixed type A/type B
inhibitor cotransin (a representative digital autoradiogram is given in S3 Fig). It was previously shown that the signal peptide of the CRF1R is cotransin-sensitive [7].
Bars are mean of three digital autoradiograms ± SD; n = 3. See also S1 Table for the data.
https://doi.org/10.1371/journal.pone.0208641.g007
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chains (RNCs) will degrade the N-terminal part of the chain that is exposed to the cytosolic
compartment (about 48 residues), generating a slightly faster migrating protein band on the
gel (directly underneath the NC-tRNA species) that correspond with the unproductive, non-
targeted RNCs (Fig 7B, lanes 9–12). If well-targeted, NCs will be shielded from exogenous pro-
tease because of a tight interaction between the ribosome and the protein-conducting channel
after transfer from SRP. If so, they will appear as intact RNCs after PK exposure. Because equal
PK-protected NC-tRNA bands were observed in DMSO and FMP-401319-3 treated samples
(Fig 7B, lanes 9–12, top band), we can rule out an inhibitory activity of this compound on tar-
geting and transfer of the NCs of CRF1R-pPL to the Sec61 complex. However, addition of PU
to the samples in order to release the NCs from the ribosome did not result in translocation
and signal peptide cleavage (SPcNC fragment; red arrow) of the chains when FMP-401319-3
was present in a higher concentration (Fig 7B, lane 6 compared to lane 5). Compound FMP-
401319-3 kept most peptide chains in the non-cleaved form as intact NC (Fig 7B, lane 6), that
were also protected from PK degradation (lane 14), indicating that FMP-401319-3 inhibits the
cotranslational translocation of CRF1R-pPL by holding the NC inside the protein-conducting
channel (see Fig 7C for an interpretation of the results). The appearance of additional peptide
fragments that are PK resistant (Fig 7B, lane 14) suggest that at least some NCs in the presence
of FMP-401319-3 may be positioned between ribosome exit tunnel and the cytosolic side of
the Sec61 complex in such a way that some parts are exposed to the cytosol and accessible to
exogenous protease (see Fig 7C for an interpretation of the results). A quantification of the
translocated amount of CRF1R-pPL under the influence of compound FMP-401319-3 at the
different concentrations is shown in Fig 7D. In comparison to the archetypic mixed type A/
type B Sec61 complex inhibitor cotransin, the compound has an approximately 3-fold lower
potency (it was previously shown that the signal peptide of the CRF1R is cotransin-sensitive
[7]).
Consistent with the results shown above, we could also postpone the administration of
compound FMP-401319-3 to the RM until targeting was completed. A similar inhibitory effect
on the translocation of CRF1R-pPL 78-mers was obtained when the microsomes were pre-
treated with the compound (i.e. drug treatment before targeting) as when the compound was
applied to the RNC/RM mixture 15 minutes after initiation of targeting (Fig 8).
Whereas these results show that FMP-401319-3 blocks cotranslational translocation at the
level of the Sec61 complex, the detailed mechanism of action of this compound remains elu-
sive. Our data suggest that compound FMP-401319-3 interferes with a step after the targeting
and transfer of the NCs to the Sec61 complex, but before the growing peptide chain has been
translocated and has reached the luminal side of the ER in a looped form where signal peptide
cleavage can occur. It should be stressed, however, that we do not know whether compound
FMP-401319-3 binds directly to the Sec61 complex or has an indirect mechanism of action.
Based on the X ray structure of the archaebacterial SecYEG [34] (S4A Fig) and the canine
cryo-EM structure of the Sec61α [35] (S4B Fig), we constructed a structure model of the
human Sec61α with a CRF1R signal peptide emerging at the lateral gate (S4C and S4D Fig).
The very large dimensions of the protein conducting channel itself, however, preclude any pre-
dictions for potential FMP-401319-3 binding sites by further in silico approaches. Of note, the
structure of FMP-401319-3 has a stretched conformational pre-orientation with a restricted
degree of flexibility, which allows it to adaptively bind to an extended binding site. Although
the compound is substantially smaller than a signal sequence (see S4D Fig for the dimensions),
there is an option that FMP-401319-3 may bind to one or even several of the contact points in
the protein-conducting channel which are normally occupied by signal sequences. We found
no apparent overall similarities of our inhibitor FMP-401319-3 to other compounds known to
interfere with the Sec61 complex. Nonetheless, it is interesting that Eeyrastatin 1, (see
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Fig 8. Compound FMP-401319-3 inhibits cotranslational translocation of CRF1R-pPL in a post targeting step. (A) Schematic
depiction of the experiment. CRF1R-pPL NCs of 78 residues were translated in the absence of microsomes before administration to
the RM for targeting. NCs were left untreated or were treated with FMP-401319-3, either applied to RM for pretreatment (pre), or
applied to the RNC/RM mixture 15 minutes after initiation of targeting but before PU release (post). (B) Representative
Screening assay for inhibitors of the Sec61 complex
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introduction) features two chlorophenyl rings, which are also present in FMP-401319-3 albeit
in a very different structural context. It remains to be determined with additional structure/
function studies whether this is of any significance.
Of note, whereas the number of inhibitors addressing the eukaryotic Sec61 complex has
grown in the last decade [4], no specific inhibitor for the prokaryotic SecYEG complex has
been reported to date (except of decatransin which inhibits both the Sec61 and SecYEG com-
plexes [36]). The detection of specific inhibitors for the SecYEG complex by using an adapted,
sequential screening assay would be extremely important since such compounds may repre-
sent antibiotics with a novel mechanism of action which are urgently needed taking the threats
arising by multi drug resistant infectious bacteria into account. Although prokaryotic SecY
and eukaryotic Sec61α are functionally and structurally closely related, the sequence identities
and similarities are not so high which may allow the development of specific prokaryotic
inhibitors (e.g. 18.7% identity and 49.6% similarity for E. coli SecY vs. human Sec61α; program
LALIGN).
Conclusion
In summary, we here established a novel sequential high throughput screening procedure that
allowed the identification of novel inhibitors for the eukaryotic SRP-Sec61 targeting/transloca-
tion pathway. The potency of the final compound FMP-401319-3 is still relatively low and
must be optimized in the future by medicinal chemistry once the structure/activity relation-
ships of the compound are known in more detail. Using a much larger compound library for
screening may be another approach to get compounds with higher potency. This is, however,
not feasible in our academic institution. Most importantly, our screening approach may pave
the way to a similar assay which may help to find inhibitors for the bacterial SecYEG complex
in the future in order to detect novel antibiotic drugs.
Supporting information
S1 Table. Percentage of translocated CRF1R-pPL in the presence of different inhibitors.
Signal intensities of the individual digital autoradiograms were used to determine the translo-
cation efficiency for construct CRF1R-pPL in the cell free in vitro transcription/translation/
translocation assay in the presence of the indicated inhibitor. The percentage translocation
was calculated as the relative amount of translocated protein versus total protein (translocated
and precursor) after compound treatment, in comparison to the corresponding DMSO control
(= 100% translocation). Shown are the % of translocation for the individual experiments sum-
marized in Figs 5 and 7. In addition, IC50 values are calculated, with mean +/- SD.
(TIF)
S1 Fig. Schematic depiction of the three technical replicates of the 1052 hit compounds
under selection and deselection conditions. For each compound (dots), the relative GFP
fluorescence of the screening target in the primary screen (CRF1R.GFP) was plotted against
the relative GFP fluorescence of the target in the secondary screen (soluble, unfused GFP). Hit
compounds are indicated in green, the 5 compounds used for further analysis are indicated in
red (see below). See Fig 2. for the calculated mean values of these 3 replicates and for %
autoradiogram of the translated and translocated CRF1R-pPL chimaera in the absence (-) or presence (+) of compound FMP-401319-
3 (300 μM). Pre = drug treatment before targeting. Post = drug treatment initiated 15 minutes (i.e., 10 + 5) after targeting. The NC and
the SPcNC fragments are indicated.
https://doi.org/10.1371/journal.pone.0208641.g008
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calculations.
(TIF)
S2 Fig. Primary sequence and build-up of the CRF1R-pPL fusion construct. CRF1R-pPL rep-
sents a fusion of the signal peptide (SP) of the CRF1R and the bovine preprolactin mature
domain. For the cell free in vitro transcription/translation/translocation experiment, mRNAs
encoding 78 residues without stop codon were used. The primary sequence is shown in the
upper panel. The 78mers contain the CRF1R signal peptide (23 residues, red), a short CRF1R
downstream sequence (7 residues, red) and a preprolactin sequence (48 residues, black).
Methionine residues suitable for [35S] labeling are indicated in blue; the dash represents the
clavage site for the signal peptidase. The lower panel shows a scheme of the construct.
(TIF)
S3 Fig. The cyclodepsipetide cotransin inhibits translocation of CRF1R-pPL. Representative
digital autoradiogram of the translated and translocated CRF1R-pPL chimaera in the absence
or presence of different concentrations of cotransin (1 μM, 10 μM, 100 μM), similar as
described in the legend to Fig 7B.
(TIF)
S4 Fig. Structural homology model of human Sec61α in complex with the signal peptide of
the CRF1R. The structure model is based on (A) the Geobacillus thermodenitrificans SecY
crystal structure and (B) the canine Sec61α cryo-EM structure both in complex with signal
peptides (OmpA, 44 amino acid residues, method X-ray diffraction, PDB entry 5EUL; and
pre-prolactin, method cryo-EM, PDB entry 3JC2) respectively. Both structures are shown with
an open lateral channel gate (backbone presentation). Based on these structural information,
we designed (C) a homology model for human Sec61α with the bound signal peptide of the
CRF1R (helical region, green) and the additional N-terminal residues from position 21 to 47.
For modelling, the structures of the helical signal peptides in complex with SecY and Sec61α
were superimposed and the fused amino acids from the SecY complex were introduced into
the canine Sec61α (with removed pre-prolactin signal peptide). These amino acid residues
were then replaced by the corresponding amino acids of the CRF1R from position His4 to
Ser47. The resulting complex was refined by side chain minimization until converging at a ter-
mination gradient of 0.2 kcal/mol�Å with constraint backbone atoms, which were released in a
second minimization step until converging at a termination gradient of 0.1 kcal/mol�Å. This
first preliminary model was additionally refined by short molecular dynamic simulations (300
K, 3 ns) and energetic minimization until converging at a termination gradient of 0.1 kcal/
mol�Å. Structural modifications to generate the homology models were performed with the
software Sybyl X2.0 (Certara, NJ, USA). For energy minimization and molecular dynamic sim-
ulations, the AMBER F99 force field was used. A surface presentation of this complex (D)
shows the signal peptide of the CRF1R embedded between helices TMH2 and TMH7 in the
open lateral gate and the following amino acid residues located inside the channel. Compound
401319–3 interferes with a step before the growing peptide chain has reached the luminal side
of the ER and before the signal peptide has left the lateral gate for cleavage. There are a multi-
tude of possibilities which could explain the mechanism of action of compound FMP-401319-
3: it may bind to one or even several of the contact points in the protein-conducting channel
which are normally occupied by signal sequences. On the other hand, it may impair the overall
helix movements inside or outside of the translocation channel which are necessary for the
conversion of Sec61α from the closed to the open state. An indirect impact on the mechanism
of action, however, could also not be excluded as yet. Structure images were produced using
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the PyMOL software (DeLano WL, version 1.5, San Carlos, CA, USA).
(TIF)
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